Browsing by Author "Onal, C."
Now showing 1 - 20 of 57
- Results Per Page
- Sort Options
Item 1.5-Tesla Magnetic Resonance-Guided Adaptive Stereotactic Body Radiotherapy for Liver Malignancies(2023) Onal, C.; Yavas, G.; Yavas, C.; Arslan, G.; Efe, E.; Haberal, M.Item Adjuvant Radiotherapy in Cervical Cancer Patients: TROD Gynecologic Group Study(2020) Gultekin, M.; Esen, C. S. Beduk; Balci, B.; Alanyali, S.; Yildirim, B. Akkus; Ergen, S. A.; Sahinler, I.; Cetin, I. Alsan; Onal, C.; Yildiz, F.; Ozsaran, Z.; 0000-0002-2742-9021; D-5195-2014Item Adjuvant Small Pelvic Radiation Therapy in Cervical Cancer Patients With Minor Risk Factors(2016) Sari, S. Yuce; Guler, O. C.; Gultekin, M.; Onal, C.; Yildiz, F.; 0000-0001-6908-3412; ABX-1273-2022; AAC-5654-2020; HOC-5611-2023Item Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse(2019) Kose, Fatih; Alemdaroglu, S.; Mertsoylu, H.; Besen, A.; Guler, O.; Simsek, S.; Erbay, G.; Onal, C.; Celik, H.Item The Clinical Outcomes Of Breast Cancer Lung Metastasis Treated With Stereotactic Body Radiotherapy(2022) Guler, O. C.; Sari, S. Yuce; Gultekin, M.; Yildiz, F.; Onal, C.Item Comparison of IMRT and VMAT Plans with Different Energy Levels Using Monte Carlo Algorithm for Prostate Cancer(2014) Guler, O. C.; Onal, C.; Arslan, G.; Sonmez, S.; HOC-5611-2023Item The Correlation Between FDG-PET Parameters and Hematologic Parameters in Patients with Esophageal Squamous-Cell Carcinoma Treated with Definitive Chemoradiotherapy(2017) Yildirim, B. Akkus; Onal, C.; Torun, N.; Ozdemir, Y.; Guler, O. C.; 0000-0001-6661-4185; 0000-0002-5597-676X; 0000-0002-2218-2074; 0000-0001-6908-3412; V-5717-2017; HOC-5611-2023; AAE-2718-2021; AAG-5629-2021; AAC-5654-2020Item Dose Escalation with Integrated Boost Using High-Field MR-LINAC in Prostate Cancer Patients(2023) Onal, C.; Arslan, G.; Yavas, C.; Efe, E.; Yavas, G.Item The Dosimetric Analysis & Clinical Outcomes of Contiguous Vertebrae SBRT in Oligometastatic Patients(2022) Guler, O. C.; Oymak, E.; Onal, C.Item Dosimetric analysis of testicular doses in prostate radiotherapy at different energy levels(2016) Onal, C.; Arslan, G.; Dolek, Y.; Efe, E.Item Dosimetric Comparison of 3-Dimensional Conformal Radiotherapy, Volumetric Modulated ARC Therapy, and Helical Tomotherapy for Postoperative Gastric Cancer Patients(2017) Onal, C.; Dolek, Y.; Yildirim, B. Akkus; 0000-0001-6661-4185; HOC-5611-2023; V-5717-2017Item Dosimetric Comparison of Simultaneous-Integrated BOOST and Sequential BOOST with VMAT or Helical Tomotherapy in Breast Cancer Patients after Breast-Conserving Surgery(2019) Onal, C.; Efe, E.; Yildirim, B. Akkus; Guler, O. C.; 0000-0001-6908-3412; AAC-5654-2020Item Dosimetric Comparison of Stereotactic Body Radiation Therapy Plans With Volumetric Arc Therapy, Helical Tomotherapy, and Raystation for Liver Metastasis(2017) Onal, C.; Efe, E.; Yildirim, B. Akkus; 0000-0001-6661-4185; HOC-5611-2023; V-5717-2017Item The Effect of ADT on ADC Change in Intermediate-Risk Prostate Cancer Patients Receiving Radiotherapy(2023) Onal, C.; Erbay, G.; Oymak, E.; Guler, O. C.; 0000-0002-1706-8680; AAK-5370-2021Item The Effect of the Time Interval between Temozolomide and Radiotherapy in Adjuvant High-Grade Glioma Treatment(2022) Oymak, E.; Demircan, V.; Senyurek, S.; Yavas, G.; Guler, O. C.; Bolukbasi, Y.; Erpolat, P.; Onal, C.Item The Feasibility of Prostate-Specific Membrane Antigen Positron Emission Tomography(PSMA PET/CT)-Guided Radiotherapy in Oligometastatic Prostate Cancer Patients(2018) Guler, O. C.; Engels, B.; Onal, C.; Everaert, H.; Van den Begin, R.; Gevaert, T.; de Ridder, M.; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0001-9108-610X; https://orcid.org/0000-0002-2742-9021; https://orcid.org/0000-0003-3633-6203; https://orcid.org/0000-0003-4556-5681; https://orcid.org/0000-0003-4433-8807; 28795303; AAC-5654-2020; HOC-5611-2023; B-1285-2018; F-3248-2016; F-4794-2013To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC (Ga-68-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on 3 metastases detected by Ga-68 PSMA PET-CT. Androgen deprivation therapy was continued in CR patients. A total of 38 metastases were treated. The involved sites were pelvic bone (n = 16), pelvic lymph nodes (n = 11), paraaortic lymph nodes (n = 6), ribs (n = 3) and vertebral body (n = 2). The median PSA prior to RT was 1.1 ng/mL (range 0.1-29.0 ng/mL). A median dose of 43.5 Gy (range 30-64 Gy) was delivered by IMRT-IGRT in 12-27 fractions. At a median follow-up of 7 months (range 2-17 months), 19 patients (83%) were in remission. Four patients (17%) developed distant recurrences. The actuarial 1-year LC, PFS and OS rates were 100, 51 (95% CI 8-83%) and 100%. Univariate analysis demonstrated a statistically significantly better PFS in CS patients as compared to CR patients (1-year PFS 67 vs. 0%, p < 0.01). One patient experienced grade 2 acute gastrointestinal toxicity. Grade 3 or more toxicity events were not observed. By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that Ga-68 PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer. Validation by randomized trials is eagerly awaited.Item The Hematologic Changes During Treatment In Cervical Cancer Patients Treated With Chemoradiotherapy(2018) Yildirim, B. Akkus; Onal, C.; Kose, F.; https://orcid.org/0000-0001-6661-4185; V-5717-2017; HOC-5611-2023Item The impact of air pockets around the vaginal cylinder on vaginal vault brachytherapy(2015) Onal, C.; Guler, O.C.; Dolek, Y.; 25562767Objective: To evaluate the incidence, size and predisposing factors for air pockets around the vaginal cylinder and their dosimetric effect on the vaginal mucosa. Methods: We investigated 174 patients with endometrial carcinoma treated with external radiotherapy (RT) and brachytherapy (BRT) (101 patients, 58%) or BRT alone (73 patients, 42%). The quantity, volume and dosimetric impact of the air pockets surrounding the vaginal cylinder were quantified. The proportions of patients with or without air pockets during application were stratified according to menopausal status, treatment modality and interval between surgery and RT. Results: Air pockets around the vaginal cylinder were seen in 75 patients (43%), while 99 patients (57%) had no air pockets. Only 11 patients (6.3%) received less than the prescribed dose (average 93.9% of prescribed dose; range, 79.0-99.2%). Air pockets were significantly fewer in pre-menopausal patients or in patients treated with the combination of external RT and BRT than in postmenopausal patients or patients treated with BRT alone. A significant correlation existed between the mucosal displacement of the air gap and the ratio of the measured dose at the surface of the air gap and prescribed dose (Pearson r = -0.775; p < 0.001). Conclusion: Air pockets were still a frequent problem during vaginal vault BRT, especially in post-menopausal patients or in patients treated with BRT alone, which may potentially cause dose reductions at the vaginal mucosa. Advances in knowledge: Air pockets around the vaginal cylinder remain a significant problem, which may potentially cause dose reduction in the target volume.Item The Impact of Hormone Therapy on Setup Errors During External Beam Radiation Therapy for Prostate Cancer(2017) Onal, C.; Dolek, Y.; Ozdemir, Y.; 0000-0002-2218-2074; HOC-5611-2023; AAG-5629-2021Item The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma(2021) Onal, C.; Sari, S. Yuce; Yavas, G.; Guler, O. C.; Yigit, E.; Oymak, E.; Gultekin, M.; Yildiz, F.
- «
- 1 (current)
- 2
- 3
- »